Inguran LLC provides genetic improvement services for the livestock industry. It offers sexed semen to the dairy and other livestock industries. The firm?s services include semen collection, in vitro fertilization, and embryo collection and transfer. The company was founded in 2004 and is headquartered in Navasota, TX.

Abbott Molecular is an emerging leader in molecular diagnostics and the analysis of DNA, RNA, and proteins at the molecular level. They are committed to exploring new clinical frontiers through the development and delivery of system and assay solutions that are designed to provide earlier disease diagnosis, selection of appropriate therapies and monitoring of disease recurrence. Their expanding portfolio brings multiples technologies that enable fast, accurate results. Their state of the art research and manufacturing facilities have hundreds of scientists who are dedicated to producing quality and reliable products. Over 350 products are available in the areas of infectious disease, oncology, genetics, and automation. Some of these products include: the m2000 system which has an extensive assay menu in infectious disease featuring Abbott RealTime technology with a broad range of assays, PathVysion HER-2 DNA Probe Kit for breast cancer, ALK Break Apart FISH Probe Kit, and UroVysion Bladder Cancer Kit are important applications of the FISH technology.

Aprogenex, Inc. manufactures surgical, medical and dental instruments and supplies. The company is headquartered in Houston, TX.

Peking University Shenzhen Hospital is a private company headquartered in Guangdong, China. The firm operates hospitals.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Guangdong Women & Children's Hospital & Health Institute is a private company headquartered in China. The firm provides hospitals and healthcare services.

Vysis develops, commercializes and markets clinical products that provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. The Company has assembled a management team experienced in developing,commercializing and marketing DNA based diagnostic products and associated genetic workstations. The Company was the first to obtain Food and Drug Administration ("FDA") clearance for a genomic product using fluorescence INSITU hybridization ("FISH"). Vysis currently markets four FDA cleared clinical products in addition to distributing over 240 research products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 28 countries. It has an installed base of over 320 proprietary genetic workstations at 224 laboratories in 18 countries. The Company has a pipeline of nine clinical products under development and an expanding list of clinical product leads based upon its collaborations with leading medical research institutions, which include the University of California, San Francisco, the Mayo Clinic, St. Jude Children's Research Hospital, the University of Chicago and the Reproductive Genetics Institute.

Genetalks is a genetic technology-based medical and health solution supplier of solutions. A few examples of technology-driven industrial innovation are medical diagnosis, smart health management, and big data in gene health.

Chengdu Cedison Biotechnology Co., Ltd., established on 2013-02-17, Business scope includes licensed projects:Veterinary drug business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Research and development of bio-based materials technology;Disinfectant sales(Free of Hazardous Chemicals);Experimental analysis instrument sales;Retailing of protective equipment for healthcare workers;Sales of hygiene products and single-use medical products;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Specialty Chemicals Sales(Free of Hazardous Chemicals);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Daily necessities sales;Household Appliances Retail;Sales of daily chemical products;Daily miscellaneous goods sales;Home Appliance Sales;Instrument sales;Office Equipment Sales;Sales of agricultural and sideline products;Camera and Equipment Sales;electronics sales;Retailing of computer software, hardware and auxiliary equipment;Sales of labor protection products;needle textile sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

BGI Genomics Co., Ltd. is a holding company that engages in development of science and technology services in genomics field. Its business scope ranges from scientific, health, agricultural and informatics. The company was founded by Wang Jian on September 9, 1999 and is headquartered in Shenzhen, China.

Peking Union Medical College Hospital, also known as Beijing Xiehe Hospital (Chinese: 北京协和医院), is a renowned general hospital in Beijing, China. It was founded in 1921 by Rockefeller Foundation and is affiliated to both Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS). During the Cultural Revolution, it was renamed the "Anti-imperialist Hospital".

Tellyes Scientific is a comprehensive technology enterprise that integrates the research and development, production, and sales of modern medical teaching products. The company engages in innovation, research, and development activities in a number of important fields with training software and a traditional Chinese medicine training system supported by contemporary technology, and offers the market twelve series and more than a thousand different types of medical virtual teaching products based on the aforementioned technologies.

CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system. CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such as CHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns.